Welcome to our dedicated page for Rain Enhancement news (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Enhancement stock.
Rain Enhancement Technologies Holdco, Inc. (NASDAQ: RAIN) is a Nasdaq-listed company focused on ionization-based weather modification technology, including rainfall generation, snow enhancement, and fog mitigation. The RAIN news feed on Stock Titan aggregates company announcements, scientific updates, and regulatory disclosures that explain how its Weather Enhancement Technology Array (WETA) platform is being tested, deployed, and evaluated.
Investors and observers following RAIN news can expect coverage of technology trials and field results, such as reports on precipitation enhancement in international locations and early indications from U.S. installations. The company’s releases discuss peer-reviewed findings that its ionization rainfall generation systems have produced statistically significant rainfall increases in randomized trials, and they provide narrative detail on how installations are designed to influence rainfall and snowpack in water-stressed regions.
RAIN news also highlights corporate and governance developments, including appointments to the board of directors and the addition of strategic and technical advisors with backgrounds in weather modification, atmospheric science, quantum physics, and corporate governance. These items provide context on how the company is building scientific and leadership capacity as it pursues commercialization of its WETA platform.
Regulatory and listing-related updates form another important category of RAIN news. The company has issued press releases and filed Form 8-K reports describing its interactions with The Nasdaq Stock Market LLC, including prior notices about continued listing standards and subsequent confirmation that its securities are listed on the Nasdaq Capital Market under the symbols RAIN and RAINW. By reviewing this news stream, readers can track both operational progress in weather enhancement projects and key corporate milestones.
Rain Therapeutics Inc. will be represented by CEO Avanish Vellanki at the Goldman Sachs 42nd Annual Global Healthcare Conference from June 8-11, 2021. He will present a corporate overview and engage in one-on-one investor meetings on June 10 at 5:30 p.m. ET. The presentation will be accessible via a webcast link and on the company's website. A replay will be available for 30 days following the event. Rain focuses on precision oncology, with its lead product RAIN-32 targeting MDM2 in various cancers.
Rain Therapeutics Inc. completed its IPO in April 2021, generating net proceeds of $121.9 million. The company plans to initiate a Phase 3 trial for RAIN-32 in well-differentiated/de-differentiated liposarcoma and an open-label Phase 2 basket trial for MDM2-amplified tumors, both set for 2H 2021. The first quarter results showed a net loss of $6.8 million compared to $2.6 million in Q1 2020, with R&D expenses significantly rising. Rain aims to end 2021 with a projected cash balance of $137 million to $147 million.
Rain Therapeutics has appointed co-founder Dr. Robert Doebele as president and chief scientific officer, enhancing its leadership as it approaches a critical Phase 3 clinical trial for RAIN-32. Dr. Doebele, an expert in precision oncology, will shape the company's strategy and operations. The leadership transition comes as Rain prepares for its Phase 3 trial for liposarcoma patients in late 2021. The company focuses on precision therapies that target oncogenic drivers, notably RAIN-32, an oral MDM2 inhibitor. Rain is positioned for growth following a recent IPO.
Rain Therapeutics Inc. has announced the pricing of its initial public offering (IPO) of 7,352,941 shares at $17.00 per share, aiming for gross proceeds of approximately $125.0 million. The shares are set to trade on the Nasdaq under the ticker symbol RAIN starting April 23, 2021. A 30-day option for underwriters to purchase an additional 1,102,941 shares at the IPO price is also provided. The offering is expected to close on April 27, 2021, subject to standard closing conditions.